Abstract
Photodynamic therapy (PDT) utilize a photosensitizing agent and light for cancer therapy. It exerts anti-cancer effect mainly by inducing vascular occlusion at the irradiated site. By controlling the irradiation area, PDT can be used in a tumor-specific manner. However, the non-specific cellular damage in the surrounding normal tissue is still a serious concern. Photoimmunotherapy (PIT) is a new type of targeted cancer therapy that uses an antibody-photon absorber conjugate (APC). The superiority of PIT to PDT is the improved target specificity, thereby reducing the damage to normal tissues. Here, we developed a novel APC targeting epithelial cell adhesion molecule (EpCAM) as well as a negative control APC that does not bind to the EpCAM antigen. Our in vitro analysis of APC cytotoxicity demonstrated that the EpCAM APC, but not the negative control, was cytotoxic to EpCAM expressing COLO 205 cells after photoirradiation, suggesting that the cytotoxicity is antigen-dependent. However, in our in vivo analysis using a mouse xenograft tumor model, decreased volume of the tumors was observed in all the mice treated with irradiation, regardless of whether they were treated with the EpCAM APC or the negative control. Detailed investig...Continue Reading
References
Apr 1, 1994·The Journal of Cell Biology·S V LitvinovS O Warnaar
Jun 24, 1998·Journal of the National Cancer Institute·T J DoughertyQ Peng
Jun 15, 2004·Oncogene·Markus MünzOlivier Gires
Sep 2, 2004·Photochemistry and Photobiology·Stuart K BislandBrian C Wilson
Apr 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kazuhiro MotokiShiro Kataoka
Jun 11, 2005·Cancer Chemotherapy and Pharmacology·F R LuoF Y Lee
Jan 11, 2007·British Journal of Cancer·P A Baeuerle, O Gires
Feb 28, 2007·British Journal of Cancer·M A ChaudryM C Winslet
Sep 27, 2007·Journal of Cellular Physiology·Antonella De LucaNicola Normanno
Jan 13, 2009·Nature Cell Biology·Dorothea MaetzelOlivier Gires
Nov 4, 2010·Cancer Cell International·Markus MünzTobias Raum
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jessica KatzAnas Younes
Nov 8, 2011·Nature Medicine·Makoto MitsunagaHisataka Kobayashi
Sep 6, 2012·Journal of Clinical Immunology·Timo RathRichard S Blumberg
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Dec 21, 2013·Molecular Cancer Therapeutics·Kohei SanoHisataka Kobayashi
Mar 29, 2014·Angewandte Chemie·Ravi V J ChariWayne C Widdison
Feb 3, 2016·Molecular Cancer Therapeutics·Michihiro IshidaToshiyoshi Fujiwara
Mar 11, 2016·Current Opinion in Immunology·Bart Ecg de Goeij, John M Lambert
Apr 15, 2016·Bioconjugate Chemistry·Daisuke ShinmiYasuhisa Shiraishi
Aug 19, 2016·Science Translational Medicine·Kazuhide SatoHisataka Kobayashi
Mar 28, 2017·Molecular Cancer Therapeutics·Fu LiChe-Leung Law
Sep 16, 2017·ESMO Open·Dorte Schou NørøxeUlrik Lassen